Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00367471 · ClinicalTrials.gov registry record · Phase 1
Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer.
A Phase 1 study of Neoplasms, Breast, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
- 3
- Study locations
NCT00367471 is a Phase 1 study of Neoplasms, Breast that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 31 participants, below the 1,064-participant average among 9 other Neoplasms, Breast trials with a reported enrollment target (97% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT00367471, a Phase 1 study of Neoplasms, Breast, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to determine the optimally-tolerated regimens (OTR) for lapatinib in combination with paclitaxel, carboplatin with and without trastuzumab in patients with metastatic breast cancer.
Conditions Studied
Interventions
- DRUG carboplatin
- DRUG trastuzumab
- DRUG paclitaxel
- DRUG lapatinib
Study Locations (3)
California
- Novartis Investigative Site - La Jolla
Indiana
- Novartis Investigative Site - Indianapolis
North Carolina
- Novartis Investigative Site - Greensboro
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2006-12-07 |
| Est. Completion | 2019-09-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00367471
The ClinicalTrials.gov registry entry for NCT00367471 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,064-participant average among 9 other Neoplasms, Breast trials with a reported enrollment target (97% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neoplasms, Breast appearing as the primary indexed condition, and to 4 interventions - of which carboplatin is the first listed.
NCT00367471 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Indiana, North Carolina.
Frequently Asked Questions
What is clinical trial NCT00367471 about?
NCT00367471 is a clinical study titled "Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer.". The purpose of this study is to determine the optimally-tolerated regimens (OTR) for lapatinib in combination with paclitaxel, carboplatin with and without trastuzumab in patients with metastatic breast cancer.
What is the current status of trial NCT00367471?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2006-12-07. Estimated completion is 2019-09-12.
What conditions does trial NCT00367471 study?
This clinical trial studies the following conditions: Neoplasms, Breast.
What interventions are being tested in trial NCT00367471?
The interventions under investigation include: carboplatin (DRUG), trastuzumab (DRUG), paclitaxel (DRUG), lapatinib (DRUG).
Who is sponsoring clinical trial NCT00367471?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00367471 being conducted?
This trial has 3 study locations across California, Indiana, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms, Breast
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Dose-escalation Vaccine Trial in HER2-overexpressing Patients With High-risk Breast Cancer
COMPLETED · Phase 1
-
Effects Of GW572016 In Combination With Docetaxel (TAXOTERE)
COMPLETED · Phase 1
-
Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease
ACTIVE NOT RECRUITING · Phase 3
-
Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer
COMPLETED · Phase 3
-
Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC
COMPLETED · Phase 2
-
Evaluating and Comparing Two Surgical Methods for Treatment of Early Stage Breast Cancer
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.